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Abstract
Recombinant Mycobacterium bovis bacille Calmette–Guèrin (rBCG) expressing three T cell epitopes of
Mycobacterium tuberculosis (MTB) Ag85B antigen (P1, P2, P3) fused to the Mtb8.4 protein (rBCG018) or a
combination of these antigens fused to B cell epitopes from ESAT-6, CFP-10 and MTP40 proteins (rBCG032) were
used to immunize Balb/c mice. Total IgG responses were determined against Mtb8.4 antigen and ESAT-6 and
CFP-10 B cell epitopes after immunization with rBCG032. Mice immunized with rBCG032 showed a significant
increase in IgG1 and IgG2a antibodies against ESAT-6 and MTP40 (P1) B cell epitopes and IgG3 against both P1
and P2 B cell epitopes of MPT40. Splenocytes from mice immunized with rBCG018 proliferated against Ag85B P2
and P3 T cell epitopes and Mtb8.4 protein whereas those from mice-immunized with rBCG032 responded against
all Ag85B epitopes and the ESAT-6 B cell epitope. CD4+ and CD8+ lymphocytes from mice immunized with
rBCG018 produced primarily Th1 type cytokines in response to the T cell epitopes. Similar pattern of recognition
against the T cell epitopes were obtained with rBCG032 with the additional recognition of ESAT-6, CFP-10 and one
of the MTP40 B cell epitopes with the same pattern of cytokines. This study demonstrates that rBCG constructs
expressing either T or T and B cell epitopes of MTB induced appropriate immunogenicity against MTB.
Introduction
Tuberculosis (TB) is one of the most prevalent diseases in
developing countries. WHO estimates that 8.7 million
new cases and approximately 1.6 million deaths occur
annually [1,2]. The current vaccine against Mycobacterium
tuberculosis, M. bovis bacille Calmette–Guèrin (BCG), is
the most widely used vaccine in preventing TB disease
especially in childhood [3,4]. However, it has also been
established that the protection afforded by BCG is highly
controversial [5]. Thus, a more effective TB vaccine is
urgently needed.
It has been reported that there was only a slight decrease
in the protective efficacy of BCG after 50 years [6]. The
intrinsic advantage of BCG as a live vector is its capability
to replicate in host macrophages. In addition, BCG can
stimulate both cellular and antibody responses and has
the possibility to stimulate prolonged memory T cell
responses [7]. Moreover, BCG is safe, stable and inexpen-
sive and thus is an attractive target for genetic manipula-
tion in order to improve its protective capability against
TB[8]. BCG also represents an effective vehicle for delivery
of heterologous antigens due to its intracellular replication
in macrophages and dendritic cells [9].
Despite the dominant dogma that the cellular immune
mechanism is primarily responsible for protection against
TB, recent evidences suggest a protective role of specific
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antibodies in the defense against intracellular microor-
ganisms such as MTB [10-14]. There is also an agree-
ment that no single mycobacterial protein or antigen will
be able to evoke all the required immune response for
effective protection [15]. Vaccine formulations encoding
multivalent mixtures of antigens are necessary to increase
the chances for covering populations with different MHC
[16].This also may stimulate the innate immune system
in providing adequate cytokine and costimulatory mole-
cules [17]. Thus, the multiantigen or multiepitope
approach is an important strategy that needs to be
explored.
In this study, T and B cell epitopes of MTB were cloned
into BCG. The immunogenicity of the rBCG expressing
three T cell epitopes of the Ag85B antigen of MTB fused
to the entire sequence of MTB8.4 protein and the same
construct fused to B cell epitopes of ESAT-6, CFP-10 and
MTP-40 proteins of MTB were evaluated to determine its
ability to induce specific humoral and cellular immune
responses against these epitopes.
Materials and methods
Design of the multiepitope MTB gene fragments
The sequences of the MTB proteins were obtained from
the UNIPROT database [18]. Linear MTB B cell epitopes
were predicted from CFP-10 [18], ESAT-6 [19], and
MTP40 [20] proteins using the BCEPRED software [21].
T cell epitopes were selected from MTB Ag85B protein
based on a previous report [22] and analyzed using the
prediction program PredBalb/c [23].
Construction of rBCG clones
Two multiepitopic constructs were designed: one contain-
ing three T cell epitopes of Ag85B protein of MTB fused
to the Mtb8.4 protein, cloned into the shuttle plasmid
pNMN018 and another with the addition of the selected B
cell epitopes upstream to the previous construct, con-
tained in the shuttle plasmid pNMN032. Both constructs
were generated using preferred mycobacterium codon
usage.
Immunization of Balb/c mice with rBCG
Balb/c mice (n = 5 per group) were immunized intraperi-
toneally (i.p.) with 2 x 106 CFU of either rBCG018 or
rBCG032 in 200 μl PBS containing 0.1% Tween 80 (PBS-
T80). A control group of mice were injected with 2 x 106
CFU of the parental BCG strain in 200 μl PBS-T80. After
30 and 60 days, the same amount of either rBCG or paren-
tal BCG was injected i.p. as boosters. Sera were collected
before each injection from the tail vein and kept at -20 °C
for IgG antibodies measurement. Subsequently, three
weeks after the last immunization the mice were sacrificed
and the spleens were asseptically removed to assess the
cellular immune response.
Construction of peptides
The peptides corresponding to the T and B cell epitopes
were commercially prepared (Peptron, Korea) and the
Mtb8.4 antigen was produced in E. coli.
Enzyme-linked immunosorbent assay (ELISA)
Total IgG and IgG1, IgG2a, IgG2b and IgG3 (only against
B cell epitopes) were measured from sera of immunized
mice by ELISA as described elsewhere. The results were
analysed using One-way ANOVA test and the differences
between pairs were determined by the Multiple Range
test. p values less than 0.05 were considered statistically
significant.
Lymphocyte proliferation assay
T and B cell epitopes or recombinant Mtb8.4 protein were
added to the cultures at a final concentration of 10 μg/ml.
RPMI medium was used as negative control and the T cell
mitogen, concanavalin A (10 μg/ml) was used as positive
control. Results were calculated as stimulation index (SI)
(SI = cpm of stimulated culture/cpm of non-stimulated
culture). SI of more than 2 was considered as positive.
Analysis of intracellular cytokines
10 μg/ml of each peptide corresponding to the T and B
cell epitopes or recombinant Mtb8.4 protein were cultured
with 2 × 106 spleen cells/ml. The cells were then stained
with 20 μl (20 μg /ml) anti-mouse IL-2, IL-4 or IFN-g
labelled with PE (BD Pharmingen). The increase in the
percentage of intracellular cytokine levels in lymphocytes
of rBCG-immunized mice was compared to those of
BCG-immunized mice and scored as high, moderate, or
weak/absent corresponding to ≥ 3 fold, ≥ 2 fold, < 2 fold
increase respectively.
Results and discussion
Antibody response against T and B cell epitopes
Significant increase in the level of total IgG against ESAT-
6 and CFP-10 B cell epitopes was observed after the third
immunization of mice with rBCG032 compared to other
groups. Increased levels of specific IgG1 were detected
against ESAT-6 (p < 0.05); IgG2a against ESAT-6 (p <
0.01) and MTP40 (P1) (p < 0.01); and IgG3 against
MTP40 (P1) (p < 0.01) and MTP40 (P2) (p < 0.05) in mice
immunized with rBCG032 compared to other groups
(Fig.1). Specific IgG2b subclass antibody was not signifi-
cantly increased against any of the epitopes.
Mice receiving rBCG018, did not produce any antibody
responses against these epitopes. ESAT-6 and CFP-10
have previously been reported to be immunogenic in
mice[24]and in non-human primates[25]. Mtb8.4 did not
elicit significant IgG response in mice immunized with
either rBCG018 or rBCG032, despite containing several
B cell epitopes. Individual IgG subclass response against
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CFP-10 did not reach significant levels despite the ele-
vated levels of total IgG produced against this epitope.
We are uncertain why this discrepancy was observed but
this may highlight the importance of measuring both
total and subclass IgG to cater for subtle but significant
changes in antibody response.
The subclass response observed against the individual
B cell epitope suggest that both, the TH1 and TH2
arms of the immune response maybe operative in this
study.
Cellular immune response against T and B cell epitopes
Proliferative response against Ag85B T cell epitopes
Splenocytes isolated from rBCG018-immunized mice
showed increased proliferative response after stimulation
with Ag85B (P2) epitope (SI = 4.9); (P3) epitope (SI = 2.5)
Figure 1 Profile of antigen-specific IgG subclasses response against ESAT-6, CFP-10, MTP40 (P1) and MTP40 (P2) B cell epitopes in Balb/c mice (n
= 5 for each group) immunized with BCG (open bars) rBCG018 (hatched bars), and rBCG032 (solid bars). The results are expressed as mean OD
at 405 nm. * p < 0.05; ** p < 0.01
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Figure 2 Lymphocyte proliferative response of rBCG032-immunized mice against the Ag85B T cell epitopes (P1, P2, P3); Mtb8.4; and the B cell
epitopes of ESAT-6, CFP-10, and MTP40 (P1 and P2). The results are expressed as SI which is defined as the mean cpm of antigen-stimulated
culture divided by the mean cpm of unstimulated culture. An SI > 2 is considered positive.
Table 1 Summary of the percentage of cells expressing selected cytokines as determined by flow cytometry. Response
(fold increase) of CD4+ and CD8+ lymphocytes from rBCG-immunized mice (rBCG018, rBCG032) was compared to
those of BCG-immunized mice (BCG).
CD4+/IL-2 Ag85B (P1) Ag85B (P2) Ag85B (P3) Mtb8.4 ESAT-6 CFP10 MTP40 (P1) MTP40 (P2)
BCG
rBCG018
rBCG032
6.7
11.5
12.5
7.4
20.6*
16.5*
4.8
11.4*
6.5
3.8
12.5**
8.6*
6.1
3.6
5.6
3.1
2.4
8.4*
4.6
3.3
6.4
6.3
4.5
5.3
CD4+/IL-4
BCG
rBCG018
rBCG032
8.5
10.1
10.4
9.3
7.7
15.8
8.5
16.9
18.4*
9.4
8.4
13.8
3.5
1.1
3.8
5.4
3.5
5.7
8.4
7.8
8.6
5.9
5.7
8.4
CD4+/IFN-g
BCG
rBCG018
rBCG032
4.6
17.4**
18.4**
8.0
21.5*
22.5*
6.4
16.6*
8.4
3.7
8.9*
7.5*
5.4
5.5
7.4
5.7
2.5
5.7
5.6
2.7
9.0
3.8
2.7
9.7*
CD8+/IL-2
BCG
rBCG018
rBCG032
12.3
21.5
25.0*
9.4
34.3**
30.5**
2.1
36.3**
30.4**
2.7
10.4**
9.8**
5.3
5.2
19.4**
3.6
6.4
18.3**
9.4
8.7
19.3*
4.7
5.5
7.4
CD8+/IL-4
BCG
rBCG018
rBCG032
5.5
16.5**
20.8**
3.7
15.5**
12.5**
7.8
16.5*
20.5*
5.7
8.4
13.8*
4.8
7.5
13.8*
4.6
8.6
11.4*
6.4
8.0
11.5
6.0
7.3
7.4
CD8+/IFN-g
BCG
rBCG018
rBCG032
5.5
20.5**
25.4**
8.7
20.5*
24.5*
6.5
19.5**
21.5**
3.8
10.5*
9.7*
9.7
13.2
15.4
4.7
10.4*
11.3*
8.4
9.9
14.3
5.9
7.7
9.5
** ≥ 3 fold increase (high response) * ≥ 2 fold increase (moderate response) ≤ 2 fold increase (weak to no response)
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as well as with Mtb8.4 protein (SI = 3.2), whereas no
response was observed against Ag85B (P1).
Splenocytes from rBCG032-immunized mice showed
strong proliferative response to all the Ag85B T cell epi-
topes (P1, P2 and P3) with SI of 3.9, 5.0 and 5.3 respec-
tively. There was no stimulation with Mtb8.4 protein. A
moderate proliferative response was detected against the
ESAT-6 B cell epitope (SI = 2.4) while all of the other B
cell epitopes were not stimulatory (Fig. 2). Splenocytes sti-
mulated with ConA proliferated vigorously (SI ≥ 20)
(results not shown).
Intracellular cytokine expression against T and B cell
epitopes and Mtb8.4 protein in animals immunized with
rBCG018 or rBCG032
Table 1 summarizes the percentage of CD4+ and CD8+
lymphocytes expressing IL-2, IL-4 and IFN-g and the
“fold” difference between stimulated cells obtained from
rBCG018 and rBCG032-immunized mice compared to
those of BCG-immunized mice.
We can conclude that some T cell epitopes may induce
the production of Th2 instead of Th1 cytokines in Balb/c
mice, and that the construction of a multi-epitope vaccine
need to ensure that the overall potential “protection” that
was intended is not compromised. In addition, it would be
necessary to test the candidate vaccines in other strains of
mice to ensure a more “universal” conclusion to be drawn.
The ability to elicit a predominant Th1 immune
response is a desirable characteristic for any vaccine
against MTB. The two vaccine candidates studied in the
present work fulfilled this characteristic. In general, both
rBCG018 and rBCG032 stimulated strong cellular
response to the T cell epitopes and for the latter strong
humoral immune response as well. Our findings suggest
that co-expression of T and B cell epitopes of MTB in
BCG stimulated both arms of the immune response
although the protective capability of rBCG expressing
both T and B cell epitopes needs further investigation.
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